Drug Safety Fears May Limit Reimporting and Shape R&D

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-02-02-2005, Volume 29, Issue 2

Concerns about risky medicines may reduce pressure to expand drug imports while boosting demand for more comparative analyses of therapies.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-02-02-2005
Governance of Future Pandemics
EMA Accepts MAAs from Sandoz for Proposed Denosumab Biosimilar
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials